News

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...
The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...
Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...
Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...
The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...